赛妥珠单抗治疗银屑病的临床研究进展

New progress in the treatment of psoriasis with certolizumab pegol

银屑病是一种慢性炎症性皮肤病,严重影响患者的生活。传统的治疗药物不良反应较多,现有的生物制剂容易产生耐药。赛妥珠单抗(certolizumab pegol,CZP)为一种聚乙二醇人源化Fab(fragment crystallizable)片段的抗肿瘤坏死因子(tumor necrosis factor,TNF)-α单克隆抗体,可用于中重度斑块型银屑病的治疗,与其他生物制剂相比,赛妥珠单抗的耐药性发生率更低,且可以用于妊娠期和哺乳期的妇女。目前的临床试验数据显示出,赛妥珠单抗具有较好的临床疗效和安全性,是治疗银屑病的一种新选择。

Psoriasis is a common, chronic inflammatory skin disease, manifested as red plaques with adherent silvery scales, which affects the lives of patients seriously. Newly developed biological agents targeting the TNF-α pathway certolizumab pegol(CZP) has been used to treat psoriasis in clinical trials. CZP seems to be a promising therapeutic option for psoriasis patients although further evidence supporting the continuing clinical program for development of CZP in psoriasis is needed.